Oncotalks hematology videos and news

ESMO

Interviews recorded at the European Socitey for Medical Oncology congress

ESMO 2019 Prof. Nagi S. El Saghir, MD; Ribociclib plus Goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients ...

ESMO 2019 Prof. Nagi S. El Saghir, MD; Ribociclib plus Goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients ...

Prof. Nagi S. El Saghir, MD from the American University of Beirut Medical Center, Beirut, Lebanon is commenting on the abstract 386TiP - Ribociclib plus Goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer - RIGHT Choice study
ESMO , Kisqali Channel , Lithuania , Albania
00:05:31
ESMO 2019 Noam Falbel Pondé, MD, PhD; A Study on the efficacy and safety of Ribociclib in combination with letrozole in Older women (≥70 years)....

ESMO 2019 Noam Falbel Pondé, MD, PhD; A Study on the efficacy and safety of Ribociclib in combination with letrozole in Older women (≥70 years)....

Noam Falbel Pondé, MD, PhD from the A.C.Camargo Cancer Center, São Paulo, Brazil is commenting on the abstract 385TiP - RIBOB : A Study on the efficacy and safety of Ribociclib in combination with letrozole in Older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced Breast cancer (aBC) with no prior systemic therapy for advanced disease
ESMO , Kisqali Channel , Lithuania , Albania
00:05:06
ESMO 2019 Paul Cottu, MD, PhD; Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), Subgroup analysis from the phase 3b CompLEEment-1 trial

ESMO 2019 Paul Cottu, MD, PhD; Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), Subgroup analysis from the phase 3b CompLEEment-1 trial

Paul Cottu, MD, PhD from the Institut Curie, Paris, France is commenting on the abstract Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial
ESMO , Lithuania , Albania , Slovenia
00:02:13
ESMO 2019 Philippe Saiag, MD, PhD; Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study​

ESMO 2019 Philippe Saiag, MD, PhD; Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study​

Philippe Saiag, MD, PhD from the University of Versailles-SQY, Versailles, France is commenting on the abstract: 1338P - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
ESMO , Lithuania , Hungary , Albania
00:02:23

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies . If you require further information and/or do not wish to have cookies placed when using the site, visit Privacy Notice.

On acceptance: use all cookie settings
On denial: use only necessary cookies